ArticleAnnals of dermatology2026
A Novel Variable-Pulse Monopolar RF Mode Selectively Targets the Upper Dermis to Improve Barrier Dysfunction in Sensitive Skin.
Article in Annals of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSensitive skin is a multifactorial condition characterized by impaired epidermal barrier function, neurosensory hyperreactivity, and inflammatory dysregulation, affecting approximately 40%-50% of adults worldwide. Despite its high prevalence, effective therapeutic options remain limited.
objectiveTo evaluate the efficacy and safety of a novel 6.78 MHz monopolar radiofrequency (RF) pulse pattern for improving both subjective symptoms and objective barrier function parameters in patients with sensitive skin.
methodsIn this prospective pilot study, ten adults with sensitive skin underwent 2 sessions of shallow mode monopolar RF treatment at 4-week intervals. Assessments were performed at baseline, week 4, and week 8, including transepidermal water loss (TEWL), stratum corneum hydration (SCH), erythema index (EI), sebum production, melanin index (MI), and patient-reported symptom scores. Safety was assessed throughout the study. In parallel, a murine model was treated using identical shallow mode parameters to evaluate epidermal remodeling, collagen regeneration, and barrier-related molecular markers.
resultsAll participants completed the study without serious adverse events. TEWL significantly decreased at weeks 4 and 8 compared with baseline (
conclusionShallow-mode monopolar RF treatment improved subjective symptoms and objective barrier-related parameters in sensitive skin with excellent tolerability, supported by preclinical findings of upper-dermal remodeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.